[go: up one dir, main page]

EP2323679A4 - CLIP HEMMER AND METHOD FOR MODULATING THE IMMUNE FUNCTION - Google Patents

CLIP HEMMER AND METHOD FOR MODULATING THE IMMUNE FUNCTION

Info

Publication number
EP2323679A4
EP2323679A4 EP09800699A EP09800699A EP2323679A4 EP 2323679 A4 EP2323679 A4 EP 2323679A4 EP 09800699 A EP09800699 A EP 09800699A EP 09800699 A EP09800699 A EP 09800699A EP 2323679 A4 EP2323679 A4 EP 2323679A4
Authority
EP
European Patent Office
Prior art keywords
hemmer
modulating
clip
immune function
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09800699A
Other languages
German (de)
French (fr)
Other versions
EP2323679A2 (en
Inventor
Martha Karen Newell
Evan Newell
Haig Keledjian
Michael Agadjanyan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
VG Life Sciences Inc
Original Assignee
University of Colorado Boulder
VG Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder, VG Life Sciences Inc filed Critical University of Colorado Boulder
Priority to EP13155864.5A priority Critical patent/EP2633864A1/en
Publication of EP2323679A2 publication Critical patent/EP2323679A2/en
Publication of EP2323679A4 publication Critical patent/EP2323679A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP09800699A 2008-07-25 2009-07-23 CLIP HEMMER AND METHOD FOR MODULATING THE IMMUNE FUNCTION Withdrawn EP2323679A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13155864.5A EP2633864A1 (en) 2008-07-25 2009-07-23 Clip inhibitors and methods of modulating immune function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13594208P 2008-07-25 2008-07-25
PCT/US2009/004328 WO2010011347A2 (en) 2008-07-25 2009-07-23 Clip inhibitors and methods of modulating immune function

Publications (2)

Publication Number Publication Date
EP2323679A2 EP2323679A2 (en) 2011-05-25
EP2323679A4 true EP2323679A4 (en) 2012-08-22

Family

ID=41570789

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13155864.5A Withdrawn EP2633864A1 (en) 2008-07-25 2009-07-23 Clip inhibitors and methods of modulating immune function
EP09800699A Withdrawn EP2323679A4 (en) 2008-07-25 2009-07-23 CLIP HEMMER AND METHOD FOR MODULATING THE IMMUNE FUNCTION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP13155864.5A Withdrawn EP2633864A1 (en) 2008-07-25 2009-07-23 Clip inhibitors and methods of modulating immune function

Country Status (4)

Country Link
EP (2) EP2633864A1 (en)
AU (1) AU2009274512A1 (en)
CA (1) CA2737146A1 (en)
WO (1) WO2010011347A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2015035414A1 (en) * 2013-09-09 2015-03-12 The Texas A&M University System Treating neurological disorders
EP3517117A1 (en) * 2018-01-30 2019-07-31 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection
US20230226135A9 (en) * 2019-07-19 2023-07-20 Bcell Solutions, Inc. Acetylcholine modulation of immune function
CA3158336A1 (en) * 2019-09-20 2021-03-25 Michiko Koga Peptide, and cell fusion agent and pharmaceutical composition for cancer therapy containing said peptide
EP3818989A1 (en) * 2020-03-12 2021-05-12 Universität Greifswald Peptides and oligonucleotides for a sars-cov-2 vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043361A2 (en) * 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2005079523A2 (en) * 2004-02-18 2005-09-01 University Of Georgia Research Foundation, Inc. Novel teleost derived antimicrobal polypeptides
WO2009055005A2 (en) * 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565354A (en) 1896-08-04 James h
US1164308A (en) 1914-11-02 1915-12-14 Nils Nilson Traction-plow.
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4415553A (en) 1973-08-06 1983-11-15 Dso "Pharmachim" Compositions, processes for their preparation and method for treatment of neoplasms
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5520914A (en) 1987-08-06 1996-05-28 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
CA2039718C (en) 1989-08-31 2003-02-25 John J. Rossi Chimeric dna-rna catalytic sequences
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5972922A (en) 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
JP3257675B2 (en) 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． Modified ribozyme
DE4216134A1 (en) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES
JPH07501451A (en) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド Multivalent antigen binding protein
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
DE69333082T2 (en) 1992-02-11 2004-05-06 Cell Genesys, Inc., Foster City OBTAINING HOMOZYGOTEM BY TARGETED GENETIC EVENTS
HUT72993A (en) 1992-08-19 1996-06-28 Merrell Dow Pharma Process to prepare phatmaceutical compns. contg antiangiogenic oligomers
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
DE69303494T2 (en) 1992-11-13 1997-01-16 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTIC LIMITED DIFFERENTIATION ANTIQUES FOR THE TREATMENT OF B CELL LYMPHOMA
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
NO941135L (en) 1993-04-01 1994-10-03 Daiichi Seiyaku Co Thiazole pyrimidine derivatives
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
WO1995018972A1 (en) 1994-01-05 1995-07-13 Arqule, Inc. Systematic modular production of aminimide- and oxazolone-based molecules having selected properties
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5618925A (en) 1994-04-28 1997-04-08 Les Laboratories Aeterna Inc. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5696092A (en) 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
US7625565B2 (en) 1995-05-01 2009-12-01 Viral Genetics, Inc. Antiviral compositions comprising lysine-rich histone fractions prepared by pepsin treatment of thymic cell nuclei
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US6245904B1 (en) * 1995-09-14 2001-06-12 The University Of Tubingen Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific T-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1997025344A1 (en) * 1996-01-03 1997-07-17 The Australian National University Clip analogues and autoimmune disease
EP0886641A2 (en) 1996-01-16 1998-12-30 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043361A2 (en) * 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2005079523A2 (en) * 2004-02-18 2005-09-01 University Of Georgia Research Foundation, Inc. Novel teleost derived antimicrobal polypeptides
WO2009055005A2 (en) * 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ADAMS SHARLENE ET AL: "Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 47, no. 9, 1 January 1997 (1997-01-01), pages 1069 - 1077, XP001526055, ISSN: 0004-4172 *
CHRISTIE G ET AL: "Alzheimer's disease: correlation of the suppression of.beta.-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome", JOURNAL OF NEUROCHEMISTRY, WILEY INTERSCIENCE, NEW YORK, NY, US, vol. 73, no. 1, 1 January 1999 (1999-01-01), pages 195 - 204, XP002209921, ISSN: 0022-3042, DOI: 10.1046/J.1471-4159.1999.0730195.X *
HILLMAN G G ET AL: "Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 10, no. 17, 1 August 2003 (2003-08-01), pages 1512 - 1518, XP009160950, ISSN: 0969-7128 *
HITZEL CHRISTOPH ET AL: "The invariant chain derived fragment clip is an efficient in vitro inhibitor of peptide binding to MHC class II molecules", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 33, no. 1, 1 January 1996 (1996-01-01), pages 25 - 31, XP009160759, ISSN: 0161-5890, [retrieved on 19990426], DOI: 10.1016/0161-5890(95)00131-X *
LU XUEQING ET AL: "Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 120, no. 2, 1 February 2007 (2007-02-01), pages 207 - 216, XP002612403, ISSN: 0019-2805, DOI: 10.1111/J.1365-2567.2006.02492.X *
STEIN R ET AL: "CD74: A new candidate target for the immunotherapy of B-cell neoplasms", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 18, 15 September 2007 (2007-09-15), pages 5556S - 5563S, XP002510850, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1167 *
WU S ET AL: "The MHC class II-associated invariant chain-derived peptide CLIP binds to the peptide-binding groove of class II molecules", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 33, no. 4-5, 1 March 1996 (1996-03-01), pages 371 - 377, XP027285074, ISSN: 0161-5890, [retrieved on 19960301] *
XU MINZHEN ET AL: "Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB, vol. 6, no. 2, 1 April 2004 (2004-04-01), pages 160 - 165, XP009115265, ISSN: 1464-8431 *

Also Published As

Publication number Publication date
WO2010011347A2 (en) 2010-01-28
EP2323679A2 (en) 2011-05-25
WO2010011347A3 (en) 2010-05-27
EP2633864A1 (en) 2013-09-04
CA2737146A1 (en) 2010-01-28
AU2009274512A1 (en) 2010-01-28
WO2010011347A9 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
EP2243036A4 (en) SYSTEM AND METHOD FOR RECORDING ACTIVITIES
EP2300808A4 (en) SYSTEMS AND METHODS FOR IMAGING USING ABSORPTION
EP2307634A4 (en) Clip and method for using the clip
DE112009000684A5 (en) System and method for multidimensional gesture evaluation
EP2366794A4 (en) PROCESS FOR PREPARING POLY-3-HYDROXYALKANOATE AND POLY-3-HYDROXYALKANOATAGGLOMERATE
EP2142078A4 (en) IMPROVED METHOD AND DEVICES FOR MATERIAL CHECK
ATE539065T1 (en) COMPOUNDS AND METHODS FOR MODULATING FX RECEPTORS
EP2360615A4 (en) SYSTEM AND METHOD FOR BIOMETRIC AUTHENTICATION
EP2344891A4 (en) MSP NANOPORES AND CORRESPONDING METHODS
DE102011050837A8 (en) Sensor and method for producing the same
DE602007000729D1 (en) Method and device for authentication
EP2356462A4 (en) ANTI-CXCR1 COMPOSITIONS AND METHOD
EP2436978A4 (en) DRYING UNIT AND METHOD FOR DRYING SOLUBLE-STORING WATER
DE602007001241D1 (en) Device for the allocation of subchannels and corresponding method
EP2513142A4 (en) MEMBRANES AND APPROPRIATE PROCEDURES FOR CLEANING ANTIBODIES
EP2238447A4 (en) DEVICES AND METHOD FOR IMMUNE SYSTEM MODELING
EP2132541A4 (en) SYSTEM AND METHOD FOR PHOTOENER DETECTION
DE102011050839A8 (en) Sensor and method for producing the same
EP2247284A4 (en) METHOD FOR MINIMIZING POLYMORPHISM
EP2349305A4 (en) PHYTOCHEMICAL COMPOSITIONS AND METHOD FOR AMP-KINASE ACTIVATION
EP2254110A4 (en) STEREOSIGNALKODIERGERÄT, STEREOSIGNALDEKODIERGERÄT AND METHOD THEREFOR
EP2458499A4 (en) METHOD AND DEVICE FOR CREATING WIDGETS
EP2289104A4 (en) DIODES AND METHOD FOR FORMING DIODES
EP2438859A4 (en) STRIPS FOR MEASURING BIODATES AND METHOD FOR MEASURING BIODATES
EP2323679A4 (en) CLIP HEMMER AND METHOD FOR MODULATING THE IMMUNE FUNCTION

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110225

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1158107

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20120724

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/08 20060101AFI20120718BHEP

Ipc: A61P 33/06 20060101ALI20120718BHEP

Ipc: A61P 31/18 20060101ALI20120718BHEP

Ipc: A61K 33/06 20060101ALI20120718BHEP

Ipc: A61P 37/08 20060101ALI20120718BHEP

Ipc: A61P 1/16 20060101ALI20120718BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130221

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1158107

Country of ref document: HK